Creso Pharma Has Sold Over 100,000 CannaQIX Packs

Creso Pharma has announced that it has sold over 2.5 million lozenges since April 2018, representing upwards of 100,000 packs sold.

Creso Pharma Limited (ASX:CPH) is pleased to announce that its flagship cannaQIX® line exceeded the significant milestone of 2.5 million lozenges sold, globally, which represents over 100,000 packs sold since its launch in April 2018.

Revenue from the sale of cannaQIX® lozenges in 2019 exceeded AUD $1 million (unaudited). The cannaQIX® hemp oil derived food supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand.

Creso Pharma developed cannaQIX® 10 to help manage stress and cannaQIX® 25 and 50 to help manage chronic pain. The initial target markets for these products were Switzerland, UK, Australia, New Zealand and Brazil. The Company produces the cannaQIX® range of products in Switzerland and is commercialising them in collaboration with several partners in Europe, Oceania and Latin America.

The products are being distributed through pharmacies and drug stores in Europe as well as through doctors and clinics in Oceania and Latin America.

We are proud that cannaQIX® has reached this milestone.

Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma

Dr. Wernli went on to say that "The cannaQIX® line is Creso Pharma's hemp oil/vitamins & minerals based food supplement, oral cosmetic and medical cannabis, which has been developed with a unique proprietary buccal delivery system. The products help manage stress and pain, and support better sleep. We are looking forward to upcoming launches together with our new partners in additional countries and continents such as South Africa and Latin America in 2020."

Jorge Wernli, Commercial Director said: "Creso Pharma's cannaQIX® hemp oil-derived products are unique, all Swiss-made, and produced in GMP facilities complying with local regulatory requirements. Creso Pharma has developed an attractive product portfolio responding to customer needs and complying with regulations. With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialized animal and human health products."

To learn more about Creso Pharma visit their company HQ here.

Disclaimer: Past performance is not an indicator of future performance.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *